ClinicalTrials.gg
CompletedNCT06464939Updated Oct 29, 2026

Phase 2 Study of KH001 in Long-term Relief From Dentin Hypersensitivity

A Phase 2 interventional study of KH001 and Placebo in Dentin Hypersensitivity, sponsored by HysensBio Co., Ltd. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by HysensBio Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Dentin Sensitivity with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. Dentin Sensitivity · United States.

Enrollment
27th of 54
120 · median 120
Started
2024
with 2 others
Phase 2
6 of 57
none open now
Registered
46th of 57
by date

Among the 57 studies in Dentin Sensitivity with a site in United States, this one is the 27th largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 in phase 2, and was the 46th registered.

Dentin Sensitivity

290 studies on the registry are indexed under Dentin Sensitivity; 48 are open to participants now.

Browse Dentin Sensitivity studies →

Open to participants now

5 of the 57 studies in Dentin Sensitivity with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Dentin Sensitivity studies recruiting now, 6 (32%) set no upper age limit and 12 (63%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Dentin Sensitivity with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of KH001 in subjects with dentin hypersensitivity.

Read the detailed description

The study will consist of a screening period, a treatment period, and a follow-up period. The total duration of the study for each subject will be approximately 8 to 12 weeks. All subjects will be randomly assigned in a 1:1:1 ratio, with Group A, Group B and Group C.

03

Conditions studied

  • Dentin Hypersensitivity

Browse trials for

Keywords

  • Dentin Sensitivity
  • Denin Hypersensitivity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 18 years old by the time of the screening visit
  • Is in good general health as determined by the investigator
  • Has at least 2 non-adjacent teeth and is diagnosed with hypersensitive

Exclusion criteria

Exclusion Criteria:

  • Is allergic to the active drug substance or other used in the product
  • Has any history of alcohol or drug abuse
  • Has received any treatment related to dentin within 8 weeks prior to the screening visit
  • Is jedged by the investigator as ineligible for participation for other reasons
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Group A

    KH001 and placebo

    Drug: KH001 · Drug: Placebo

  • Experimental
    Group B

    KH001 and placebo

    Drug: KH001 · Drug: Placebo

  • Placebo comparator
    Group C

    Placebo

    Drug: Placebo

Interventions

  • DrugKH001

    Application of KH001 over a 1 or 2-week period

  • DrugPlacebo

    Applications of water for injection

06

What researchers measure

Primary outcomes

  1. Change from baseline in Schiff sensitivity score

    Schiff sensitivity score 0-3 by an evaporative air

    Time frame: Baseline and Week 5

Secondary outcomes

  1. Change from baseline in a Schiff sensitivity score

    Schiff sensitivity score 0-3 by an evaporative air

    Time frame: Baseline, Up to 8 Weeks

  2. Change from baseline in a Tactile threshold

    Tactile threshold by yeaple probe

    Time frame: Baseline, Up to 8 Weeks

  3. Change from baseline in Visual Analogue Scale

    Visual Analogue Scale by an evaporative air

    Time frame: Baseline, Up to 8 Weeks

07

Study locations

2 sites
  • ADA Forsyth
    Cambridge, Massachusetts 02142, United States
  • Forsyth Institute
    Cambridge, Massachusetts 02142, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Dec 2025, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jun 18, 2024
StartActual
Oct 8, 2024
Primary completionActual
Dec 22, 2025
CompletionActual
Dec 22, 2025
Results delay requested
Oct 27, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, registry dates and arm descriptions
2 updates, last Oct 29, 2026
Show all 2 updates
  1. Oct 29, 2026
    Minor edits only
    + 1 other change: arm descriptions
  2. Oct 28, 2026
    Minor edits only
    + 2 other changes: verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06464939
Lead sponsor
HysensBio Co., Ltd
Collaborators
The Forsyth Institute
Responsible party
Sponsor
First posted
Jun 18, 2024
Start date
Oct 8, 2024
Primary completion
Dec 22, 2025
Completion
Dec 22, 2025
Last update
Oct 29, 2026

Study contacts

Hatice Hasturk
principal investigator · ADA Forsyth

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KH001

Start the discussion